258 related articles for article (PubMed ID: 26946938)
21. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.
Kennedy NA; Clark A; Walkden A; Chang JC; Fascí-Spurio F; Muscat M; Gordon BW; Kingstone K; Satsangi J; Arnott ID; Lees CW
J Crohns Colitis; 2015 Jan; 9(1):41-9. PubMed ID: 25135754
[TBL] [Abstract][Full Text] [Related]
22. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
23. Calprotectin in Daily Practice: Where Do We Stand in 2017?
D'Angelo F; Felley C; Frossard JL
Digestion; 2017; 95(4):293-301. PubMed ID: 28511188
[TBL] [Abstract][Full Text] [Related]
24. [Fecal calprotectin: a diagnostic tool for inflammatory bowel disease].
Fraga M; Godat S; Nydegger A; Moradpour D; Schoepfer AM
Rev Med Suisse; 2012 Sep; 8(352):1669-70, 1672-3. PubMed ID: 22988727
[TBL] [Abstract][Full Text] [Related]
25. Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation.
Gearry R; Barclay M; Florkowski C; George P; Walmsley T
N Z Med J; 2005 May; 118(1214):U1444. PubMed ID: 15886739
[No Abstract] [Full Text] [Related]
26. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
27. Clinical usefulness of the faecal calprotectin test in suspected paediatric inflammatory bowel disease.
Akobeng AK
Acta Paediatr; 2018 Nov; 107(11):2019-2023. PubMed ID: 29706011
[TBL] [Abstract][Full Text] [Related]
28. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease.
Fagerberg UL; Lööf L; Lindholm J; Hansson LO; Finkel Y
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):414-20. PubMed ID: 18030206
[TBL] [Abstract][Full Text] [Related]
29. [Measurement of calprotectin in faeces].
Jahnsen J; Røseth AG; Aadland E
Tidsskr Nor Laegeforen; 2009 Apr; 129(8):743-5. PubMed ID: 19373299
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.
Zhang W; Wong CH; Chavannes M; Mohammadi T; Rosenfeld G
BMJ Open; 2019 Apr; 9(4):e027043. PubMed ID: 30987989
[TBL] [Abstract][Full Text] [Related]
31. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.
An YK; Prince D; Gardiner F; Neeman T; Linedale EC; Andrews JM; Connor S; Begun J
Med J Aust; 2019 Nov; 211(10):461-467. PubMed ID: 31680263
[TBL] [Abstract][Full Text] [Related]
32. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
Fu Y; Wang L; Xie C; Zou K; Tu L; Yan W; Hou X
Sci Rep; 2017 Jun; 7(1):2669. PubMed ID: 28572616
[TBL] [Abstract][Full Text] [Related]
33. How to use faecal calprotectin in management of paediatric inflammatory bowel disease.
Saha A; Tighe MP; Batra A
Arch Dis Child Educ Pract Ed; 2016 Jun; 101(3):124-8. PubMed ID: 26848103
[TBL] [Abstract][Full Text] [Related]
34. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
Dajti E; Frazzoni L; Iascone V; Secco M; Vestito A; Fuccio L; Eusebi LH; Fusaroli P; Rizzello F; Calabrese C; Gionchetti P; Bazzoli F; Zagari RM
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1120-1131. PubMed ID: 37823411
[TBL] [Abstract][Full Text] [Related]
35. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
David LE; Surdea-Blaga T; Dumitrascu DL
Sao Paulo Med J; 2015; 133(4):343-9. PubMed ID: 26039537
[TBL] [Abstract][Full Text] [Related]
36. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
Gacesa R; Vich Vila A; Collij V; Mujagic Z; Kurilshikov A; Voskuil MD; Festen EAM; Wijmenga C; Jonkers DMAE; Dijkstra G; Fu J; Zhernakova A; Imhann F; Weersma RK
Gut Microbes; 2021; 13(1):1943288. PubMed ID: 34313538
[TBL] [Abstract][Full Text] [Related]
37. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis.
Petryszyn P; Staniak A; Wolosianska A; Ekk-Cierniakowski P
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1306-1312. PubMed ID: 31464777
[TBL] [Abstract][Full Text] [Related]
38. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
39. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
Menees SB; Powell C; Kurlander J; Goel A; Chey WD
Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
[TBL] [Abstract][Full Text] [Related]
40. [Faecal calprotectin in inflammatory bowel diseases: review].
Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
